Onco Actu du 26 mai 2020

	1.1 BIOLOGIE - GÉNOME
Study reveals first evidence inherited genetics can drive cancer’s spread [Rockefeller University] A new study, published May 25 in Nature Medicine, suggests that differences in a single gene (ApoE4), carried within someone’s genome from birth, can alter progression of melanoma, a type of skin cancer. The researchers suspect these inherited variations may have the same effect on other types of cancer as well.
	4.15 DÉP., DIAG. & PRONO. - IMAGERIE
New double-contrast technique picks up small tumors on MRI [EurekAlert!] The UC Davis team created a probe that generates two magnetic resonance signals that suppress each other until they reach the target, at which point they both increase contrast between the tumor and surrounding tissue. They call this two-way magnetic resonance tuning (TMRET). The work is published May 25 in the journal Nature Nanotechnology.
	5.1 TRAITEMENTS - PRÉ-CLINIQUE
Study eyes partially-lost essential genes as possible targets in cancer [Broad Institute] The study – published in Nature Communications, and relying in part on data from the Cancer Cell Line Encyclopedia, the Cancer Dependency Map project, The Cancer Genome Atlas (or TCGA), and the Exome Aggregation Consortium (now gnomAD) database, among others – identified more than 1,200 “essential genes” that could serve as targets for future therapies.
	5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS
For the first time, a combination of immunotherapy and chemotherapy has been shown to be effective in patients with pancreas cancer [VHIO] The data obtained suggests that blocking CXCR4 and PD1 can increase the benefit of chemotherapy in pancreas cancer, and this justifies confirmation in a subsequent randomized test,” said Dr Macarulla, who added that in January BL-8040 was classified as an orphan drug by the European Drug Agency.
	5.12.6 IMMUNOTHÉRAPIES - AMM
FDA Approves Nivolumab Plus Ipilimumab for First-Line Metastatic NSCLC with PD-L1 Tumour Expression ≥1% [ESMO] FDA also approved the PD-L1 IHC 28-8 pharmDx as a companion diagnostic device.
	5.2.1 PHARMA - PARTENARIATS
AstraZeneca collaborates with ArcherDX to use personalised cancer assays to detect minimal residual disease in lung cancer trials [AstraZeneca] Collaboration to focus on newly launched global Phase III MERMAID-1 trial for patients with resected, early-stage non-small cell lung cancer.
	6. LUTTE CONTRE LES CANCERS
Pressing a post-coronavirus reset button on cancer research [Institute of Cancer Research] Interestingly the second decade of the current millennium bought rapid advances in modulating the immune system and no doubt a further decade will lead to further new therapies – but the low-hanging fruits have been picked and further output is not immune to the law of diminishing returns.
	6.15 LUTTE CONTRE LES CANCERS - COVID-19
Virtual Cancer Care During and Beyond the COVID-19 Pandemic: We Need to Get It Right [JCO Oncology Practice] Once we obtain and analyze data on VCC, we need to use this insight to design tools that represent and address the needs, wants, and perspectives expressed by patients and their caregivers.